share_log

Goldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Raises Price Target to $12

Benzinga ·  Aug 9 23:49  · Ratings

Goldman Sachs analyst Paul Choi maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Neutral and raises the price target from $10 to $12.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment